Agents for preventing and treating disorders involving modulation of the ryanodine receptors
The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.
1. A compound which is selected from the group consisting of formula I-g, I-h, I-k-1, I-l-1, or I-m-1: wherein
(a) the compound of formula I-g or I-h is:
wherein W is S or O;
n is 0, 1, or 2;
q is 0, 1, 2, 3, or 4;
each R is located at position 6, 7, 8 or 9 on the benzothiazepine ring;
each R is independently selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino may be substituted or unsubstituted;
R 15 and R 16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted; and
R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-)arylthio may be substituted or unsubstituted;
provided that
when q is 0 and n is 0, then —C(═W)NR 15 R 16 is not —C(═O)NH 2 , —C(═O)NHPh, —C(═S)NH-nButyl, or —C(═O)NHC(═O)CH 2 Cl;
when q is 0, n is 0 or 2, then —C(═W)NR 15 R 16 is not —C═ONHPh, —C═ONHCOCH 2 Cl, —C═ONH 2 , —C═ONH(n-Bu), —C═S(NHPh), —C═S(NHCOCH 2 Cl), —C═S(NH 2 ), or —C═SNH(n-Bu);
(b) the compound of formula I-k-1 is:
wherein
n is 0, 1, or 2;
R 18 is selected from the group consisting of —NR 15 R 16 , —C(═O)—NR 15 R 16 , —OR 15 , —C(═O)—OR 15 , alkyl, aryl, cycloalkyl and heterocyclyl, wherein each alkyl, aryl, cycloalkyl and heterocyclyl may be unsubstituted or substituted;
R 15 and R 16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;
p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
R′ is selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-)arylthio may be substituted or unsubstituted; and
R″ is H;
provided that when n is 0, and R′ is OH or C 1 -C 3 alkoxyl, then —(CH 2 ) p —R 18 is not —(CH 2 ) 3-4 -benzylpiperidine;
(c) the compound of formula I-l-1 is:
wherein
n is 0, 1, or 2;
R 6 is selected from the group consisting of —OR 15 , —NHNR 15 R 16 , —NHOH, —CH 2 X, acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
R 15 and R 16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;
X is selected from the group consisting of halogen, —CN, —CO 2 R 15 , —C(═O)NR 15 R 16 , —NR 15 R 16 , —OR 15 , —SO 2 R 7 , and —P(═O)R 8 R 9 ;
R 7 is selected from the group consisting of —OR 15 , —NR 15 R 16 , —NHNR 15 R 16 , —NHOH, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
R 8 and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and
R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted; or
(d) the compound of formula I-m-1 is:
wherein
n is 0, 1, or 2;
R 8 and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-) arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted.
2. The compound of claim 1 having the formula of I-g or I-h:
wherein W is S or O;
n is 0, 1, or 2;
q is 0, 1, 2, 3, or 4;
each R is located at position 6, 7, 8 or 9 on the benzothiazepine ring;
each R is independently selected from the group consisting of halogen, —OH, —NH 2 —NO 2 , —CN, —CF 3 —OCF 3 , —N 3 —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-) aryl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)aryl, (hetero-)arylthio, and (hetero-)arylamino may be substituted or unsubstituted;
R 15 and R 16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted; and
R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-) arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted.
3. The compound of claim 2 , wherein W is O.
4. The compound of claim 3 , wherein R 15 and R 16 independently are selected from the group consisting of H, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted.
5. The compound of claim 1 , having the formula I-k-1:
wherein
n is 0, 1, or 2;
R 18 is selected from the group consisting of —NR 15 R 16 , —C(═O)—NR 15 R 16 , —OR 15 , —C(═O)—OR 15 , alkyl, aryl, cycloalkyl and heterocyclyl, wherein each alkyl, aryl, cycloalkyl and heterocyclyl may be unsubstituted or substituted;
R 15 and R 16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;
p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
R′ is selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-)arylthio may be substituted or unsubstituted; and
R″ is H.
6. The compound of claim 1 having the formula I-l-1:
wherein
n is 0, 1, or 2;
R 6 is selected from the group consisting of —OR 15 , —NHNR 15 R 16 , —NHOH, —CH 2 X, acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
R 15 and R 16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH 2 , alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R 15 and R 16 together with the N to which they are bonded may form a heterocycle which may be substituted or unsubstituted;
X is selected from the group consisting of halogen, —CN, —CO 2 R 15 , —C(═O)NR 15 R 16 , —NR 15 R 16 , —OR 15 , —SO 2 R 7 , and —P(═O)R 8 R 9 ;
R 7 is selected from the group consisting of —OR 15 , —NR 15 R 16 , —NHNR 15 R 16 , —NHOH, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
R 8 and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and
R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-)arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted.
7. The compound of claim 1 having the formula I-m-1:
wherein
n is 0, 1, or 2;
R 8 and R 9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted;
R′ and R″ are independently selected from the group consisting of H, halogen, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —N 3 , —SO 3 H, —S(═O) 2 alkyl, —S(═O)alkyl, —OS(═O) 2 CF 3 , acyl, alkyl, alkoxyl, alkylamino, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, (hetero-)arylthio, and (hetero-) arylamino; wherein each acyl, alkyl, alkoxyl, alkylamino, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, and (hetero-) arylthio may be substituted or unsubstituted.
8. A compound selected from the group consisting of:
and a salt thereof.
9. The compound of claim 1 , wherein the compound is S64
or its HCl salt.
10. The compound of claim 8 , wherein the compound is S107
or its pharmaceutically acceptable salt.
11. The compound of claim 10 , wherein the salt is the HCl salt.
12. The compound of claim 1 , wherein the compound is S111
or its pharmaceutically acceptable salt.
13. The compound of claim 12 , wherein the salt is the HCl salt.
14. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising one of the compounds according to claim 8 , and a pharmaceutically acceptable carrier.
16. A method of treating a disorder or a disease in a subject, or reducing the risk of sudden cardiac death in a subject who is considered to be subject to such risk, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 to effectuate the treatment, wherein the disorder or disease is selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome; wherein the cardiac disorders and diseases are selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; heart failure, congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure; wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence; and wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.
17. The method of claim 16 , wherein the compound is administered to the subject to treat cardiac disorders and diseases selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure.
18. The method of claim 17 , wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof.
19. The method of claim 16 , wherein the compound is administered to the subject to treat skeletal muscular disorders and diseases selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence.
20. The method of claim 16 , wherein the compound is administered to the subject to treat cognitive disorders and diseases selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.